LSTA
Lisata Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.50 / 10
Netural
Capital flow assessment shows a robust 7.0/10, highlighting positive liquidity despite mixed trend signals across different flow sizes. Analyst coverage is neutral with no historical win rate, and sentiment is lukewarm, underscoring the need for vigilance on both market expectations and potential legal issues regarding the company's sale.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-21
InstitutionBrookline Capital
Times predicted2
Historical Win Rate0.0%
Is money flowing into or out of LSTA?
- LSTA holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.50/10 (Netural).
